Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone for severe disruptive behavior disorders in children and adolescents
2006-002207-13Phase 2Completed
- Sponsor
- University of Freiburg Medical Center Department of Child and Adolescent Psychiatry
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS) comparing Zeldox with Placebo (2 arms). Primary endpoints: Change from baseline in NCBRF-TIQ conduct problem subscore and Change from baseline in NCBRF-TIQ oppositional behavior subscore. Started May 2006; status: completed.
02
Drugs
ziprasidone
03
Conditions
conduct disorder (CD)oppositional defiant disorder (ODD)disruptive behavior disorder not otherwise specified (DBD-NOS)
Beyond the preview
Go deeper on 2006-002207-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002207-13.